Finally, a review of 156 patients treated on SWOG protocols failed to find a significant prognostic impact from NPM1 or FLT3 mutations, either separately or in combination, in the elderly AML cohort (≥65 years old).42 These same authors also reviewed outcomes from a cohort of 1258 UK Medical Research Council/National Cancer Research Institute (MRC/NCRI) patients, which included 448 patients older than 65 years and 810 patients between 55 and 65 years old. This evidence concerns the gene NPM1 and acute myeloid leukemia.